Apollomics (APLM) vs RenovoRx (RNXT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
RenovoRx (RNXT) has outperformed Apollomics (APLM) over the past year, gaining 18.3% versus a gain of 7.4%. Over five years, RNXT leads with a -85.3% price change compared with -98.4% for APLM. RenovoRx is the larger company by market cap ($45.5 million vs $45.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APLM | RNXT |
|---|---|---|
| Share price | $15.54 | $0.942 |
| Market cap | $45.28M | $45.45M |
| 1-day change | -6.92% | -10.29% |
| YTD return | -16.90% | +12.14% |
| 1-year return | +7.43% | +18.34% |
| 5-year return | -98.43% | -85.26% |
| EPS (TTM) | $-0.25 | $-0.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $1.12M |
| Revenue growth (YoY) | — | +2511.63% |
| Net income (latest FY) | $-53.86M | $-11.17M |
| Gross margin | — | 70.88% |
| Operating margin | — | -1113.98% |
| Net margin | — | -994.48% |
| 52-week high | $28.29 | $2.59 |
| 52-week low | $12.58 | $0.77 |
| Distance from 52-week high | -45.09% | -63.63% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +656.90% |
| Average volume | 11.07K | 815.75K |
| Shares outstanding | 2.91M | 48.25M |
| Employees | 14 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RNXT has outperformed APLM by 10.9 percentage points over the past year.
About Apollomics
APLM stock →Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About RenovoRx
RNXT stock →RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
APLM vs RNXT FAQ
Which is bigger, Apollomics or RenovoRx?
RenovoRx (RNXT) is larger, with a market capitalization of $45.45M compared with $45.28M for Apollomics (APLM).
Which stock has performed better over the past year, APLM or RNXT?
RNXT returned +18.34% over the past 12 months, compared with +7.43% for APLM (price return, excluding dividends). Past performance does not predict future results.
Are Apollomics and RenovoRx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.